Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Ray Kim

Showing results (21-30 of 248) with videos related to

Pageof 25
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2014
Coffee: a panacea or snake oil for the liver?Radhika Kumari, W Ray Kim
European Journal of Gastroenterology & Hepatology|May 29, 2004
Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfallsKiran Bambha, W Ray Kim
The American Journal of Gastroenterology|May 21, 2009
Hyponatremia in hepatic encephalopathy: an accomplice or innocent bystander?Byung Cheol Yun, W Ray Kim
Gastroenterology|February 24, 2010
Predicting response to pegylated interferon/ribavirin-based therapy in genotype 1 chronic hepatitis C patients: results of 3 independent genome-wide association studiesSumeet K Asrani, W Ray Kim
Health Economics|August 31, 2002
Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantationDavid J Vanness, W Ray Kim
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 25, 2011
Surveillance for hepatocellular carcinoma in patients with cirrhosisJu Dong Yang, W Ray Kim
Clinical Liver Disease|April 17, 2019
Epidemiology of Hepatitis B Virus Infection in the United StatesBo Hyun Kim, W Ray Kim
Gastroenterology|August 26, 2010
Rifaximin in hepatic encephalopathy: is an ounce of prevention worth a pretty penny?Michael D Leise, W Ray Kim
Clinics in Liver Disease|October 5, 2002
Medical and economic impact of autoimmune hepatitisJayant A Talwalkar, W Ray Kim
Clinics in Liver Disease|January 20, 2009
The international normalized ratio of prothrombin time in the model for end-stage liver disease score: a reliable measurePatrick S Kamath, W Ray Kim
Pageof 25

Showing results (21-30 of 248) with videos related to

Sort By:
Pageof 25
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2014
Coffee: a panacea or snake oil for the liver?Radhika Kumari, W Ray Kim
European Journal of Gastroenterology & Hepatology|May 29, 2004
Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfallsKiran Bambha, W Ray Kim
The American Journal of Gastroenterology|May 21, 2009
Hyponatremia in hepatic encephalopathy: an accomplice or innocent bystander?Byung Cheol Yun, W Ray Kim
Gastroenterology|February 24, 2010
Predicting response to pegylated interferon/ribavirin-based therapy in genotype 1 chronic hepatitis C patients: results of 3 independent genome-wide association studiesSumeet K Asrani, W Ray Kim
Health Economics|August 31, 2002
Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantationDavid J Vanness, W Ray Kim
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 25, 2011
Surveillance for hepatocellular carcinoma in patients with cirrhosisJu Dong Yang, W Ray Kim
Clinical Liver Disease|April 17, 2019
Epidemiology of Hepatitis B Virus Infection in the United StatesBo Hyun Kim, W Ray Kim
Gastroenterology|August 26, 2010
Rifaximin in hepatic encephalopathy: is an ounce of prevention worth a pretty penny?Michael D Leise, W Ray Kim
Clinics in Liver Disease|October 5, 2002
Medical and economic impact of autoimmune hepatitisJayant A Talwalkar, W Ray Kim
Clinics in Liver Disease|January 20, 2009
The international normalized ratio of prothrombin time in the model for end-stage liver disease score: a reliable measurePatrick S Kamath, W Ray Kim
Pageof 25